MACCLESFIELD, England, May 7 /CNW/ - Cyprotex today (7th May 2009)
launches Cloe(R) Gateway, a new secure web portal for access to drug discovery
services. The initial offering via Cloe(R) Gateway is a new enhanced version
of our proprietary predictive software, Cloe(R) PK, which predicts whole body
pharmacokinetics from simple in vitro ADME and physicochemical properties.
Commenting on the launch, Dr Anthony D. Baxter, Cyprotex's Chief
Executive Officer, said:
"I am delighted to announce the launch of our new and novel web portal
Cloe(R) Gateway and its first product, an improved version of Cloe(R) PK.
Cloe(R) PK, as a server based product, has been used by many of our customers
for prediction of pharmacokinetic properties from early ADME data and found it
to be very useful in decision making for candidate selection. Cyprotex have
invested considerable time and effort improving the Cloe(R) PK model and we
are proud to launch version 2.1 as an online service available via Cloe(R)
Gateway. This will enable many more of our customers to utilise this excellent
product on a simple pay-per-use model. The cost effectiveness of this approach
will allow access of such predictive technologies to new audiences of
scientists such as bench medicinal chemists.
This approach to selling software solutions is new to the
ADME/pharmacokinetic world and we anticipate it will grow to replace
competitor products still being sold on the outdated server/license model.
The pharmaceutical industry has amassed a huge quantity of ADME data over
the past few years and the availability of an online version of Cloe(R) PK
though Cloe(R) Gateway will enable those companies to realise tremendous real
added value from that data in the form of pharmacokinetic performance
characteristics to enable faster, cheaper and better designed drugs to be
I look forward to announcing further new products to be sold through
Cloe(R) Gateway such as a human intestinal absorption model and a product to
enable customers to access our largest selling product Cloe(R) Screen in the
For further information:
For further information: Cyprotex PLC, Helen Gill PhD, Product
Development Manager, Tel: +44(0)1625-505-100, email@example.com,